GH vs. SOLV: Guardant Health vs. Solventum Stock Comparison

Company Profile

Guardant Health (GH) and Solventum (SOLV) both fall under the Health Care Equipment & Services industry group, but GH is classified in Health Care Providers & Services while SOLV is classified in Health Care Equipment & Supplies.

Guardant Health (GH) has been public since October 4, 2018, giving it a longer listed trading history, while Solventum (SOLV) listed on March 26, 2024 and still has a shorter public-market record.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Guardant Health (GH) has an aggressive beta of 1.69, indicating higher sensitivity to broad-market moves, while Solventum (SOLV) is defensive at 0.62 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Capital efficiency shows on one side only: Solventum (SOLV) earns 3.19% on shareholders’ equity, ranked against its industry; Guardant Health (GH) has no ROE this period.

Guardant Health (GH) reports a negative net margin of -37.93%, usually indicating a net loss over the period. Meanwhile Solventum (SOLV) reports 1.91%, ranking against industry peers normally.

Guardant Health (GH) reports a negative operating margin of -37.06%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Solventum (SOLV) reports 6.82%, ranking against industry peers normally.

Profitability Metrics

Growth

Guardant Health (GH) at 32.88% sits in the top revenue growth quartile, while Solventum (SOLV) at 0.86% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: Solventum (SOLV) reports EPS growth of 221.74%, ranked against its industry; Guardant Health (GH) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Guardant Health (GH) at 3.60 keeps current ratio within its industry’s typical mid-range, while Solventum (SOLV) at 1.03 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for SOLV.

Only one side’s leverage can be read here: Solventum (SOLV) carries debt-to-equity ratio of 1.10 against its industry range, while Guardant Health (GH) reports no figure this period.

Financial Strength Metrics

Dividends

Neither Guardant Health (GH) nor Solventum (SOLV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Guardant Health (GH) nor Solventum (SOLV) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Solventum (SOLV) trades at 101.55 times trailing earnings, ranked against its peers, while Guardant Health (GH) has no P/E ratio this period.

Solventum (SOLV) at 1.88 prices around its industry’s typical P/S ratio, while Guardant Health (GH) at 15.96 clears its benchmark range — GH looks notably rich on sales.

Guardant Health (GH) reports a negative P/B ratio of -73.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Solventum (SOLV) reports 3.20, ranking against industry peers normally.

Valuation Metrics